Skip to contentH
Haemonetics Corp
H
HAEHaemonetics Corp Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$330.60M$330.60Mderived−3.7% vs Q4 2024 Net Income$57.98M$57.98Mderived+184.7% vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Haemonetics Corp · CIK 313143 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$193,050,000+9.7% Operating Incomederived$71,335,000+138.2% Operating Cash Flowderived$116,557,000+81.9% Free Cash Flowderived$100,914,000+75.8% Margins · derivedGross margin58.4%+7.2 pt vs Q4 2024
Operating margin21.6%+12.9 pt vs Q4 2024
Net margin17.5%+11.6 pt vs Q4 2024
ended Mar 29, 2025 · filed May 21, 2025 · 53 d after period end